Original Article
Expression of ASPH protein in retroperitoneal liposarcoma and its clinical significances
Mengmeng Xiao, Shibo Liu, Yuqing Cui, Lihua Wang, Jun Chen, Chengli Miao, Xiaosong Rao, Xuesong Chen, Xiaoqun Dong, Wands Jack, Chenghua Luo
Published 2019-08-25
Cite as Chin J Gen Surg, 2019, 34(8): 700-703. DOI: 10.3760/cma.j.issn.1007-631X.2019.08.015
Abstract
ObjectiveTo investigate the expression of Aspartate Beta-Hydroxylase (ASPH) in retroperitoneal liposarcoma (RL)and evaluate its clinical significances.
MethodsRelevant clinical data of 69 RL cases after surgical resection were collected. The expression of ASPH in tumor tissues was detected by immunohistochemistry. The CTL epitopes of ASPH protein HLA-A2 were predicted by SYFPEITHI and NetMHCpan software.
ResultsThe overall positive rate of ASPH expression for the whole group was 81%, that for well-differentiated liposarcoma was 73%, dedifferentiated liposarcoma was 87%(P<0.05). ASPH expression was positively correlated with the postoperative recurrence free survival rate (P<0.05). Five HLA-A2 restricted CTL epitopes (9 peptides) were screened with the method of motif prediction.
ConclusionsASPH expression is positively correlated with the degree of malignancy of RL, and the ASPH expression is an independent risk factor for postoperative recurrence free survival rate of RL. Moreover, ASPH was found to have 5 HLA-A2 restricted CTL epitopes, which are expected to be used for the immunotherapy of RL.
Key words:
Liposarcoma; Retroperitoneal tumors; Survival rate; Immunotherapy
Contributor Information
Mengmeng Xiao
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China
Shibo Liu
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China
Yuqing Cui
Department of Oncology, Cancer Hospital Affiliated to Harbin Medical University, Harbin 150081, China
Lihua Wang
Department of Pathology, Peking University International Hospital, Beijing 102206, China
Jun Chen
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China
Chengli Miao
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China
Xiaosong Rao
Department of Pathology, Peking University International Hospital, Beijing 102206, China
Xuesong Chen
Department of Oncology, Cancer Hospital Affiliated to Harbin Medical University, Harbin 150081, China
Xiaoqun Dong
The Liver Research Center of Warren Alpert School of Medicine, Brown University 02903, USA
Wands Jack
The Liver Research Center of Warren Alpert School of Medicine, Brown University 02903, USA
Chenghua Luo
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing 102206, China
